10-K: Progyny Reports Strong 2025 Growth, Expands Health Solutions

Progyny, Inc. announced a 10% revenue increase to $1.29 billion in 2025, driven by expanded fertility and family building solutions and a growing client base, alongside a new $200 million share repurchase program.

Summary

• Total revenue increased by 10% to $1.29 billion for the year ended December 31, 2025, up from $1.17 billion in 2024.
• Net income grew by 7.7% to $58.5 million in 2025, compared to $54.3 million in 2024.
• Adjusted EBITDA increased by 11.7% to $222.1 million in 2025, from $198.8 million in 2024.
• Gross profit rose 20% to $304.5 million, with gross margin improving by 190 basis points to 23.6% in 2025.
• The client base expanded to over 590 employers, covering approximately 7.2 million lives under contract as of December 31, 2025.
• The company launched a new $200 million share repurchase program in November 2025, having already repurchased $81.7 million by year-end.
• Acquired Benefit Bump LLC in January 2025 and Apryl GmbH in June 2024, expanding women's health and family building solutions.
• Michael Sturmer, Chief Operating Officer, terminated employment in December 2025 and transitioned to a consulting role effective January 1, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with solid revenue and profit growth, expanding market reach, and positive operational efficiencies. The strategic acquisitions and share repurchase program further bolster a positive outlook, despite some increases in G&A expenses and a decrease in interest income.

Positives

• Strong revenue growth of 10% year-over-year, reaching $1.29 billion.
• Net income increased by 7.7% to $58.5 million.
• Adjusted EBITDA grew by 11.7% to $222.1 million, indicating healthy operational performance.
• Significant gross profit increase of 20% and a 190 basis point improvement in gross margin to 23.6%, reflecting operational efficiencies.
• Expanded client base to over 590 employers and increased covered lives to 7.2 million, demonstrating successful market penetration.
• High client retention, with substantially all clients renewing since 2016.
• Industry-leading Net Promoter Scores (NPS) of +81 for fertility benefits and +79 for Progyny Rx as of December 31, 2025, indicating high member satisfaction.
• Successful expansion into new solutions like pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing.
• Ongoing share repurchase program (November 2025 program for up to $200 million) signals confidence in company value and returns capital to shareholders.
• Established a $200 million revolving credit facility, providing additional liquidity and financial flexibility.
• Superior clinical outcomes for Progyny members compared to national averages, including a 46.7% live birth rate per attempted retrieval (vs. 36.8% for all patients at same clinics) and a 96.6% single embryo transfer rate (vs. 80.8% for all patients at same clinics).

Negatives

• Interest and other income, net decreased by 36% to $10.155 million in 2025, primarily due to a decrease in investment income and an increase in interest expense.
• General and administrative expenses increased significantly by 21% to $147.094 million, partly due to incremental headcount, executive severance costs ($7.7 million), and a $4.1 million increase in bad debt expense.
• Cash and cash equivalents decreased from $162.3 million in 2024 to $112.2 million in 2025.
• One large client, which accounted for 12% of total revenue in 2024, terminated its services agreement effective January 1, 2025, although transition care was provided until June 30, 2025.
• Utilization rate for female-only members slightly decreased from 1.07% in 2024 to 1.04% in 2025.

Risks

• Failure to meet publicly announced guidance or other expectations could cause stock price decline.
• Highly competitive market with established players and new entrants, potentially leading to declining market share if the company cannot compete effectively.
• Unfavorable global economic conditions (e.g., recession, inflation, interest rate fluctuations, geopolitical conflicts) could limit business growth and negatively affect results.
• Dependence on retaining existing clients and increasing adoption of services within the client base; any failure to do so would harm the business.
• Loss of large clients or changes in pricing terms, especially given a significant number of clients are in the technology industry, could negatively impact revenue.
• Inability to attract new clients would adversely affect business, financial condition, and results of operations.
• Significant changes in the utilization of solutions (consumption rate or mix) could adversely affect financial performance.
• Operating in a highly regulated industry with evolving legal and regulatory requirements, including PBM regulation and reproductive rights laws, could lead to increased compliance costs or operational restrictions.
• Acquisitions, strategic investments, or partnerships pose integration challenges, divert management attention, disrupt business, and could dilute stockholder value.
• Limited operating history with the current platform of solutions makes future results difficult to predict.
• Potential negative publicity in the health benefits industry could adversely affect business, financial condition, and results of operations.
• Information technology system failures or cybersecurity breaches (including those of third parties) could lead to service disruption or loss of confidential information.
• Use of artificial intelligence may subject the company to new legal, regulatory, ethical, operational, or other challenges, including potential flaws, bias, or intellectual property issues.
• Dependence on maintaining the Center of Excellence network of high-quality fertility specialists; failure to do so would limit future growth.
• Reliance on strategic relationships with third parties (channel partners, vendors, insurance carriers); failure to maintain these could impair competitiveness.
• Risk of supply chain disruptions or inefficiencies in the pharmacy distribution network affecting Progyny Rx.
• Exposure to credit risk from members for co-payments, co-insurance, and deductibles.
• Challenges and risks associated with doing business with government entities.
• Failure to enforce intellectual property rights could impair the ability to protect proprietary technology and brand.
• Potential limitation on utilizing net operating loss carryforwards due to ownership changes.
• Changes in effective tax rate or tax liabilities could adversely affect results of operations.
• Certain U.S. state tax authorities may assert a state nexus and seek to impose state and local taxes, which could adversely affect results of operations.
• Changes in accounting principles generally accepted in the United States or incorrect estimates/judgments could adversely affect reported financial results.
• Stock price volatility and potential decline due to various factors, including market fluctuations, analyst reports, and future stock sales.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition of the company more difficult.
• Designation of Delaware courts as the exclusive forum for certain stockholder actions could discourage lawsuits against the company or its directors, officers, or other employees.

Future Outlook

Progyny anticipates continued growth by expanding its client base, capitalizing on embedded growth within existing clients, and introducing new solutions and services in women's health and family building. The company expects to expand its addressable market to include large group fully insured employers and continues to evaluate opportunities for acquisitions and new offerings. Guidance for Q1 2026 and full year 2026 was issued on February 26, 2026.

Management Comments

• "We envision a world where everyone can realize their dreams of family and ideal health."
• "Our mission is to empower healthier, supported journeys through transformative fertility, family building and womens health benefits."
• "We have achieved this growth by demonstrating that our purpose-built, data-driven and disruptive platform consistently delivers superior clinical outcomes in a cost-efficient manner, while driving exceptional client and member satisfaction."
• "We believe the value proposition we deliver to all of these constituents is key to our success and growth."
• "We believe our addressable market primarily consists of large self-insured employers as well as labor populations under the Labor Management Relations Act of 1947 (also known as the Taft-Hartley Act) and federal government populations."
• "We estimate that our current member base of 7.2 million covered lives under contract represents a mid-single digit percent of our total market opportunity."
• "We anticipate expanding our addressable market to include large group fully insured employers."
• "We believe we are the leader in the market for employer-sponsored womens health and family building solutions."
• "Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025... and concluded that our internal control over financial reporting was effective."

Industry Context

StockSavvy.ai notes that Progyny operates in a rapidly evolving and highly competitive healthcare industry, particularly within the niche of employer-sponsored women's health and family building solutions. The company's expansion into broader women's health areas like pregnancy, postpartum, menopause, and midlife aligns with a growing trend of holistic employee benefits. The increasing scrutiny and regulation of Pharmacy Benefit Managers (PBMs), as highlighted by the Consolidated Appropriations Act of 2026 and FTC actions, represent a significant industry challenge that Progyny Rx must navigate. The company's data-driven approach and focus on superior clinical outcomes differentiate it in a market where health insurance companies and venture-backed solutions also compete, often with greater brand recognition or broader integration capabilities. Consolidation within the healthcare industry, including financial investors acquiring fertility practices, could intensify competition and impact provider network dynamics.

Comparison to Industry Standards

• Progyny's in-network average live birth rate per attempted retrieval for Progyny members is 46.7%, significantly higher than the 36.8% average for all patients at those same clinics and the national average of 34.9% (based on 2022 CDC data).
• The single embryo transfer rate for Progyny members is 96.6%, substantially higher than the 80.8% average for all patients at the same clinics and the national average of 78.9% (based on 2021 SART data). This indicates a focus on best practices that reduce risks associated with multiple births.
• Progyny members experience a lower IVF multiples rate of 2.1% compared to the national average of 5.8% (based on 2022 CDC data), demonstrating superior clinical outcomes and cost avoidance for clients.
• The typical Progyny member undergoes 2.1 retrievals for a live birth, compared to the national average of 3.6 retrievals, representing substantial cost avoidance and reduced stress.
• Progyny's Net Promoter Score (NPS) of +81 for fertility benefits and +79 for Progyny Rx are industry-leading, suggesting high customer satisfaction compared to general healthcare industry benchmarks which are often much lower.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings or claims are currently known that would have a material adverse effect on the company's financial position or results of operations.

Related Party Transactions

• The filing incorporates information on 'Certain Relationships and Related Transactions' by reference from the 2026 Proxy Statement, but does not detail any specific related party dealings within the 10-K itself.

Stakeholder Impact

• Shareholders: Potential for continued stock price appreciation due to growth and share repurchases, but also risks from market volatility and anti-takeover provisions. Dilution risk from future equity awards.
• Employees: Access to comprehensive women's health and family building benefits, competitive compensation, and development opportunities. Potential for increased productivity and retention.
• Customers (Clients): Measurable financial value through cost management, superior clinical outcomes for their employees, and enhanced employee productivity and retention.
• Members (Employees/Dependents): Healthier, more supported journeys through transformative fertility, family building, and women's health benefits, including concierge support and access to a premier network of specialists.
• Providers and Specialists: Increased patient volumes, elimination of financial risk associated with collections, data sharing, and support for utilizing the latest technologies and best practices.
• Creditors: Improved financial health and access to a $200 million revolving credit facility enhance the company's ability to meet its obligations.

Next Steps

• Continue expanding the client base of self-insured employers in the United States.
• Capitalize on embedded growth potential within the existing client base.
• Expand Progyny benefits solutions within existing clients by offering incremental services and new solutions.
• Evaluate new services and addressable markets, including large group fully insured employers, and potential acquisitions.
• Issue definitive proxy statement for the 2026 Annual Meeting of Stockholders within 120 days after December 31, 2025.
• Continue to evaluate the impact of the Consolidated Appropriations Act of 2026 on its consolidated financial statements as additional guidance is issued.
• Melissa Cummings' trading plan terminates on the earlier of all shares sold or March 31, 2027.
• Michael Sturmer will provide consulting services from January 1, 2026, to December 31, 2026, with automatic one-year renewals unless notice of non-renewal is given.

Key Dates

Recommendation

Progyny demonstrates robust financial performance with significant revenue and net income growth, coupled with an improving gross margin. The company's strategic expansion into broader women's health solutions and its strong client acquisition and retention rates indicate a substantial and growing market opportunity. The ongoing share repurchase program signals management's confidence in the company's valuation. While there are increased G&A expenses and a decrease in interest income, the core business drivers remain strong, and the company's differentiated, data-driven platform continues to deliver superior clinical outcomes and high member satisfaction, positioning it well for long-term value creation.

Keywords

Fertility Benefits, Family Building, Womens Health, Progyny Rx, Health Benefits Management, SEC Filing, 10-K, Financial Results, Corporate Governance, Share Repurchase, Acquisitions, Healthcare Technology, Employee Benefits, Nasdaq, PGNY